Please login to the form below
oral GLP-1 drug
This page shows the latest oral GLP-1 drug news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Novo won US Food and Drug Administration (FDA) approval for Rybelsus in September 2019, when it became the first oral alternative to injectable GLP-1 agonists. ... The two companies first teamed up in 2007 when Novo signed an initial licence agreement
Latest news
-
Lilly’s Trulicity scores CV reduction indication in the US
The new MACE approval could help Lilly in its fight for market share with other GLP-1 agonists, including Novo Nordisk’s once-weekly drug Ozempic (semaglutide). ... Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto
-
Novo Nordisk preps for speedy oral GLP-1 drug filing
Despite that competition Novo’s older GLP-1 drug Victoza (liraglutide) – given as a daily injection – held up remarkably well in 2018, with sales up 5% to 24.3bn krone, while ... Oral semaglutide is seen as critical to Novo’s hopes of maintaining
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Oral biologics delivery still elusive
market. Some peptides - such as transplant rejection drug cyclosporine and diuretic hormone desmopressin acetate - are simple enough to be amenable to standard oral formulation technologies and so have been available for ... Oramed - whose technology
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
The Difference Collective
Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
